Viventia Biotechnologies Inc.

Details Viventia Biotechnologies Inc. Viventia Biotechnologies Inc.

www.viventia.com

Ontario

Toronto GTA

Mississauga

Corporation

active

Viventia Biotech Inc. is a Canadian biopharmaceutical company developing Armed Antibodiesâ„¢, powerful and precise anti-cancer drugs designed to overcome various forms of cancer. Viventia€™s lead product is Proxiniumâ„¢, which combines a cytotoxic protein payload significantly more powerful than traditional chemotherapies with the highly precise tumour-targeting characteristics of a monoclonal antibody. Proxiniumâ„¢ is in clinical development for the treatment of head and neck cancer and bladder cancer, and is expected to enter advanced clinical trials in 2006.
Country of Ownership: Canada
Year Established: 1995
Exporting: Yes
Primary Industry (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Primary Business Activity: Manufacturer / Processor / Producer
Number of Employees: 50

Services:
Biotechnology

Products:
Pharmaceuticals and biologicals, Molecular biology and genetic engineering

Technology:
Fully Human Monoclonal Antibodies

Affiliated with

Also associated with

No associations

Rating

Viventia Biotechnologies Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.

If you have personal experience with Viventia Biotechnologies Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viventia Biotechnologies Inc. will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-COD-O-5748